These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24800434)

  • 1. Patent law for the dermatologist.
    Mei DF; Liu J
    Semin Cutan Med Surg; 2013 Dec; 32(4):242-6. PubMed ID: 24800434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for strengthening patent protection of pharmaceutical inventions in light of federal court decisions.
    Pillai X; Kinney WA
    Curr Top Med Chem; 2010; 10(18):1929-36. PubMed ID: 20615184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents.
    Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Beyer A; Visaria J
    Food Drug Law J; 2009; 64(1):171-81. PubMed ID: 19998745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inventions and Patents: A Practical Tutorial.
    Mehta H; Tidwell L; Liotta LA
    Methods Mol Biol; 2017; 1606():379-397. PubMed ID: 28502014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WTO: US and Argentina settle dispute over patents and data protection.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2002 Dec; 7(2-3):65. PubMed ID: 14743805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patenting inventions in the field of biology and chemistry: German and European patent law and case law.
    Vossius V
    Naturwissenschaften; 1997 Oct; 84(10):431-43. PubMed ID: 9394296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-to-invent versus first-to-file: impact of the AIA.
    Rachinsky T; Sullivan C; Ghosh S; Resnick DS; Burton C; Armstrong M; Hanish JP; Sklan A
    Pharm Pat Anal; 2014 Jul; 3(4):353-9. PubMed ID: 25291309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The quest for market exclusivity in biotechnology: navigating the patent minefield.
    Gersten DM
    NeuroRx; 2005 Oct; 2(4):572-8. PubMed ID: 16489366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patents and the supply of therapeutic products.
    Hayhurst WL
    Law Med Health Care; 1992; 20(3):235-7. PubMed ID: 1434767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?
    Sampat BN; Amin T
    J Health Polit Policy Law; 2013 Aug; 38(4):735-55. PubMed ID: 23645877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethical and intellectual property in the biological sciences.
    Maher EA
    Cell Mol Biol (Noisy-le-grand); 1997 May; 43(3):263-7. PubMed ID: 9193780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patent first, ask questions later: morality and biotechnology in patent law.
    Bagley MA
    William Mary Law Rev; 2003 Dec; 45(2):469-547. PubMed ID: 15570677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent protection for protein structures and databases.
    Meyers TC; Turano TA; Greenhalgh DA; Waller PR
    Nat Struct Biol; 2000 Nov; 7 Suppl():950-2. PubMed ID: 11103996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A guide to drug discovery. Protecting your inventions: the patent system.
    Webber PM
    Nat Rev Drug Discov; 2003 Oct; 2(10):823-30. PubMed ID: 14526385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Specificities of patent protection in the pharmaceutical industry: modalities and traits of intellectual property].
    Jannuzzi AH; Vasconcellos AG; de Souza CG
    Cad Saude Publica; 2008 Jun; 24(6):1205-18. PubMed ID: 18545747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bio-patents, development and society: on the patentability of human genes.
    Myszczuk AP; de Meirelles JM
    Rev Derecho Genoma Hum; 2012; (37):37-60. PubMed ID: 23520914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of gene patents viewed from the United States Patent Office.
    Mossinghoff GJ
    Adv Genet; 2003; 50():13-21; discussion 507-10. PubMed ID: 14714684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.